Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedFooter text updated to Revision: v3.6.6. Sponsor/branding lines referencing Moffitt Cancer Center and 'Helpful Links Provided by' were removed.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedThe page revision has been updated to v3.6.5, replacing the previous v3.6.4. This is a metadata update and does not modify the study information or content shown on the page.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page footer now shows Revision: v3.6.4, replacing v3.6.3. This indicates a minor software/version update with no changes to study details or how to participate.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3 in the footer. This represents a minor site version update and does not alter any study details or page content.SummaryDifference0.1%

- Check79 days agoChange DetectedA new Revision tag shows v3.6.2 on the page, replacing v3.6.0, indicating a minor update to the page template or backend. No visible study information or actions appear to be changed.SummaryDifference0.1%

- Check93 days agoChange DetectedRecruitment status on the study page now indicates 'No longer looking for participants', signaling that enrollment is closed. New help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and the Intervention/Treatment header formatting was standardized, accompanied by a revision note (Revision: v3.6.0).SummaryDifference0.6%

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.